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Reward Value of Cigarette Smoking
for Comparably Heavy Smoking Schizophrenic, 
Depressed, and Nonpatient Smokers
Bonnie Spring, Ph.D.
Regina Pingitore, Ph.D.
Dennis E. McChargue, Ph.D.
Objective: The study goal was to de-
termine whether schizophrenic and de-
pressed smokers perceive the reinforce-
ment value of cigarette smoking differently
from nonpsychiatric smokers who smoke
as heavily.
Method: The authors assessed the pref-
erences for smoking cigarettes versus en-
gaging in other pleasant activities, the
perceived advantages and disadvantages
of smoking, and the amount of reinforce-
ment that would be needed to attain
smoking abstinence among 26 schizo-
phrenic, 26 depressed, and 26 nonpsychi-
atric heavy smokers.
Results: Both schizophrenic and de-
pressed participants chose smoking as
their preferred activity more often than
nonpsychiatric smokers, and they did not
differ from each other. The patients also
exceeded the comparison group in the
benefits they ascribed to smoking and felt
they would require more incentives to
quit, but they attributed comparable
drawbacks to smoking.
Conclusions: Schizophrenic and de-
pressed smokers recognize many draw-
backs associated with smoking, but
compared to nonpatients who smoke as
heavily, they also perceive more benefits
and find cigarettes more appealing than
alternative rewards. The heightened re-
ward value of smoking warrants attention
in tailoring tobacco control interventions
for schizophrenic and depressed smokers.
(Am J Psychiatry 2003; 160:316–322)
Cigarette smoking remains the greatest preventable
cause of death and disease in the United States (1, 2). After
declining steadily for several decades, the prevalence of
smoking stabilized in 1990 and since has decreased only
minimally (3). The plateau in the smoking rate derives
partly from several subpopulations of recalcitrant smok-
ers who have been unable to quit (4, 5).
Schizophrenic and depressed smokers are two sub-
groups that have been especially difficult to reach. A de-
cade-long antismoking campaign that made most hospi-
tals smoke-free (6–8) has done little to decrease rates of
smoking by psychiatric patients. Nor have either generic
or selectively targeted treatments achieved notable suc-
cess in promoting smoking cessation among either
schizophrenic (9–12) or depressed (13, 14) individuals.
Only about 1% of the population is affected by schizophre-
nia, but the prevalence of nicotine dependence among
schizophrenic people is very high (58%–92%) (15–18). Ma-
jor depression affects about 15% of the population and has
a smoking prevalence rate of 31%–61% (15, 19, 20), higher
than that for the general population (20%–30%) (3) but
lower than that for schizophrenia. Thus, comorbidity of
nicotine dependence with these two forms of psychopath-
ology affects a substantial segment of the population, add-
ing to health care expenditures (21–23). Higher rates of
smoking in schizophrenia and depression cannot be ex-
plained by differences in socioeconomic status, occupa-
tion, education, marital status, caffeine intake, or institu-
tionalization, because they persist even after the effects of
these confounding variables are taken into account (15).
The influences that make schizophrenic patients espe-
cially likely to smoke could be the same ones that lead de-
pressed individuals to smoke, or they could differ. Conse-
quently, we tested two alternative hypotheses: 1) diagnostic
specificity: that schizophrenic patients find smoking more
rewarding than depressed patients, and 2) psychopatho-
logic commonality: that schizophrenic and depressed
smokers find smoking similarly more rewarding than do
comparison smokers without psychiatric disorders other
than nicotine dependence.
The substantially higher prevalence of smoking in
schizophrenia than depression suggests diagnostic speci-
ficity, which might reflect schizophrenia’s unique patho-
physiology or treatment. For example, schizophrenic pa-
tients may smoke to reduce the side effects of neuroleptic
medications (24), although support for that proposition
has been mixed (25–27). Also, schizophrenic patients may
smoke to alleviate negative symptoms (11). Nicotine may
be particularly reinforcing in schizophrenia because it
stimulates the subcortical reward system and the prefron-
tal cortex, which both appear to be hypofunctional in
schizophrenia (28–30). Through its action at nicotinic
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cholinergic receptors, nicotine increases firing of dopa-
mine neurons in mesocorticolimbic pathways, enhancing
dopamine release in both the nucleus accumbens and
prefrontal cortex (28). Dopamine deficiency and low met-
abolic activity in these regions have been linked to the
negative symptoms (29) and sensory gating deficits (31)
that characterize schizophrenia.
Alternatively, smoking might function to ameliorate be-
havioral and biological vulnerabilities that are shared by
schizophrenic and depressed individuals. For example,
self-administering nicotine through smoking might tran-
siently help to ameliorate anhedonia: a diminished capac-
ity for pleasure that is evident in both schizophrenia and
depression (32, 33). Nicotine’s ability to directly trigger
dopamine release in mesolimbic reward centers may ren-
der smoking one of few remaining reinforcers that schizo-
phrenic and depressed patients experience as pleasurable
(34). There are functional interactions between the cholin-
ergic system and other neurotransmitter systems (e.g.,
glutamate, γ-aminobutyric acid [GABA], serotonin) that
are abnormal in the two disorders. Self-administering nic-
otine may, therefore, serve to medicate affective, cogni-
tive, and behavioral problems that arise from dysfunction
in several neurotransmitter systems (28, 35, 36).
In this study we compared several aspects of the rein-
forcing value of smoking for schizophrenic, depressed,
and nonpsychiatric comparison subjects. One facet was
the perceived advantages (“pros”) and disadvantages
(“cons”) associated with smoking. We predicted that a de-
cisional “balance sheet” of either the patients generally or
the schizophrenic patients particularly would show that
their perception tipped more strongly than that of com-
parison subjects toward believing that the pros of smoking
outweigh the cons. We further expected that the biased
decisional balance would result from the perception that
smoking has both more pros and fewer cons than per-
ceived by the comparison subjects. The rationale for pre-
dicting greater pros was that smoking should serve as a
potent negative reinforcer particularly for schizophrenic
patients, and perhaps more generally for psychiatric pa-
tients, because it dispels troublesome psychiatric symp-
toms (e.g., negative symptoms and medication side effects
for schizophrenic patients, attentional problems and dys-
phoric mood for both schizophrenic and depressed pa-
tients). The rationale for predicting fewer perceived cons
of smoking was that the cognitive deficits and social isola-
tion that occur especially in schizophrenia but also in de-
pression (37–39) might insulate patients from learning to
fully appreciate the negative consequences of smoking.
In addition to the perceived pros and cons of smoking,
we also evaluated two other aspects of smoking’s reward
value. One was participants’ reported preferences for en-
gaging in smoking rather than alternative pleasant activi-
ties. We expected that either the schizophrenic patients
specifically or both psychiatric groups would show greater
than normal preferences for smoking over other activities.
The rationale was that smoking may remain one of few de-
pendable sources of pleasure by virtue of its ability to di-
rectly trigger dopamine release. Finally, we also appraised
reward value by quantifying how much of each of a variety
of rewards smokers felt they would require in order to quit
smoking permanently. We predicted that schizophrenic
patients particularly or patients generally would feel they
needed greater than normal rewards to quit.
To validly test the study hypotheses, the research design
needed to control for smoking rate. Otherwise, apparent
differences between patients and normal subjects could
arise spuriously from the fact that patients, especially
schizophrenic ones, tend to smoke heavily (15). So that
differences between psychiatric and nonpsychiatric smok-
ers would not be attributable to different smoking rates,
we compared psychiatric outpatients to a normal compar-
ison group of firefighters, a group characterized by heavy
smoking (40).
Method
The study had 78 participants: 26 with schizophrenia (disorga-
nized subtype, N=9; paranoid, N=9; catatonic, N=4; undifferenti-
ated, N=4), 26 with major depression (recurrent in all cases), and
26 nonpsychiatric comparison smokers. The schizophrenic and
depressed subjects were outpatients receiving treatment at an ur-
ban psychiatric rehabilitation center. All of the schizophrenic pa-
tients were taking typical neuroleptics; the depressed patients
were taking either selective serotonin reuptake inhibitors or tricy-
clic antidepressants. The nonpsychiatric comparison smokers
were employees at a local fire station. The eligibility criteria re-
quired that participants be older than 18 years of age, smoke
more than 15 cigarettes per day, and lack evidence of gross cogni-
tive impairment (evidenced by a Mini Mental State Examination
[41] score higher than 24).
A pilot study was conducted to determine whether the schizo-
phrenic and depressed patients could be diagnosed reliably on
the basis of chart review and whether the nonpatients’ screening
interview reports of psychiatric symptoms corresponded to the
results of semistructured interviews. An advanced clinical psy-
chology graduate student administered the patient version of the
Structured Clinical Interview for DSM-III-R (SCID) (42) to seven
schizophrenic patients and five depressed patients from the reha-
bilitation center and the nonpatient version to five firefighters.
Findings of 100% concordance between the SCID and chart
review diagnoses for the patients and between the SCID and
screening interview diagnoses for the nonpatients supported the
use of screening interview diagnoses, supplemented for patients
by chart review.
Nonpsychiatric comparison smokers were excluded if they
presented evidence of any current or past axis I disorder other
than nicotine dependence. Psychiatric participants were ex-
cluded if they exhibited comorbid axis I disorders other than
schizophrenia, depression, and nicotine dependence. Those with
schizoaffective disorder were excluded. The interviewer also as-
sessed demographic and smoking characteristics and adminis-
tered the Fagerstrom Tolerance Questionnaire (43) to measure
physical dependence on nicotine. After complete description of
the study to the subjects, written informed consent was obtained.
Assessments were usually performed on a single day, during
which participants could take smoking breaks.
Perceived pros and cons of smoking were assessed by a modi-
fied 28-item version of the Decisional Balance Scale (44). Partici-
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pants indicated their agreement with 14 possible advantages and
14 possible disadvantages of smoking by rating each item 1 (dis-
agree), 2 (agree), or 3 (strongly agree). The scale was altered to
make it more suitable for psychiatric patients by simplifying the
wording, making it appropriate for administration by an inter-
viewer, and adding items to assess positive and negative effects
on psychiatric symptoms (e.g., “When I smoke, I enjoy everything
more in life”; “Sometimes smoking makes me hear noises, voices,
or sounds that other people don’t hear”). Each subscale score
ranged from 14 to 42, and internal consistency was high for both
the pro (Cronbach’s alpha=0.81) and con (alpha=0.82) subscales.
A decisional balance index was also computed by converting the
scores on both subscales to z scores and subtracting the score for
cons from the score for pros (44).
Preferences for engaging in smoking versus other rewarding
activities were measured by a questionnaire developed for this
study. The test required participants to make 15 forced choices
between smoking and a variety of rewards likely to be accessible
and enjoyed by psychiatric patients (e.g., eating their favorite
candy, seeing a movie, receiving a gift). The choice of smoking
was scored as 1; the choice of the other reward was scored as 0.
Scores on the preferences questionnaire ranged from 0 to 15, and
the test exhibited acceptable internal consistency (alpha=0.74).
The magnitude of reward felt necessary for quitting was mea-
sured by a rewards questionnaire created for this study. The ques-
tionnaire asked how much of each of 15 rewards (e.g., candy, coffee,
money) participants would need to quit smoking permanently.
The amount of each reward was scored from 1 to 7, yielding a total
score ranging from 15 to 105. Higher numbers indicated a need for
more rewards to quit smoking. Further information and copies of
the test instruments are available from the first author on request.
Results
All three groups of participants were nicotine-depen-
dent, heavy smokers who had smoked since their teenage
years (Table 1). Univariate analysis of variance (ANOVA)
detected no differences among the groups in the number
of cigarettes smoked daily. The percentages of women in
the three groups were as follows: schizophrenic, 26.9% (N=
7); depressed, 50.0% (N=13); comparison, 19.2% (N=5);
lambda indicated that the proportion could not be pre-
dicted on the basis of diagnostic group. The patients were
older and more physically dependent on nicotine (Table
1), so the analyses accounted for those differences. Age
and Fagerstrom score were treated as covariates in the
analyses of decisional balance, preferences for smoking,
and rewards needed to quit, because the assumptions un-
derlying analysis of covariance (ANCOVA) were met for
these outcomes. ANCOVA could not be used to analyze
pros and cons because the slopes of the regressions pre-
dicting these outcomes from age and Fagerstrom score
were not parallel across the groups. Therefore, for the
analysis of pros and cons, age and Fagerstrom score were
transformed to discrete variables and treated as ANOVA
blocking factors, making it possible to examine any inter-
actions with group (45). Age was dichotomized as ≤36
years versus older, and Fagerstrom score was trichoto-
mized as ≤7 versus 8 versus ≥9. Pros and cons were ana-
lyzed by two univariate ANOVAs rather than by multivari-
ate analysis of variance, because they were uncorrelated
(r=0.07, df=78). For all analyses, two a priori orthogonal
contrasts examined the alternative hypotheses that the
schizophrenic patients differed from the depressed pa-
tients (diagnostic specificity) and that the two patient
groups differed from the nonpatients (psychopathologic
commonality).
Analysis of the decisional balance indexes, controlling
for age and Fagerstrom score, indicated that the groups dif-
fered significantly (F=15.2, df=2, 73, p<0.001). Consistent
with psychopathologic commonality, the patients, com-
pared to the normal subjects, attributed relatively greater
advantages than disadvantages to smoking (F=27.9, df=1,
73, p<0.001), and there were no significant differences be-
tween the schizophrenic and depressed patients. The pos-
itive decisional balances shown by the schizophrenic
(mean=10.31, SD=4.74) and depressed (mean=11.81, SD=
3.29) smokers indicated that both groups appraised the ad-
vantages of smoking as greatly outweighing the disadvan-
tages. In contrast, the index approached zero for the non-
psychiatric comparison subjects (mean=0.42, SD=3.52),
indicating that they judged the pros and cons of smoking
nearly equivalent.
As expected, the groups differed significantly on how
strongly they endorsed the pros of smoking (Figure 1), and
there were no interactions with age or Fagerstrom score.
Consistent with psychopathologic commonality, the pa-
tients exceeded the comparison subjects in the pros they
ascribed to smoking (F=187.0, df=1, 75, p<0.001). The
scores of the schizophrenic patients (mean=32.85, SD=
3.71) and depressed patients (mean=33.88, SD=3.48) did
not differ significantly and were both higher than that of
the comparison subjects (mean=22.77, SD=2.32). Unex-
pectedly, the groups failed to differ in their perceptions of
the negative consequences of smoking (comparison:
mean=22.35, SD=2.87; schizophrenic: mean=22.54, SD=
TABLE 1. Demographic and Smoking Characteristics of Schizophrenic, Depressed, and Nonpsychiatric Heavy Smokers
Characteristic
Patients With
Schizophrenia (N=26)
Patients With
Major Depression (N=26)
Nonpsychiatric
Comparison Subjects (N=26)
Mean SD Mean SD Mean SD
Age (years)a 40.00 10.85 35.31 11.13 26.20 11.69
Education (years) 11.81 2.15 13.21 2.24 12.96 1.01
Packs smoked per day 1.85 0.85 1.83 0.84 1.81 0.72
Age when smoking began (years) 15.88 5.46 14.50 4.56 14.73 3.64
Score on Fagerstrom Tolerance Questionnaireb 9.04 1.68 9.00 1.57 7.54 1.82
a Significant difference among groups (F=10.2, df=2, 76, p<0.001).
b Significant difference among groups (F=6.6, df=2, 76, p<0.01).
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2.45; depressed: mean=22.08, SD=2.84), and there was no
interaction with age or Fagerstrom score. The results,
shown in Figure 1, indicate that the schizophrenic and de-
pressed patients recognized the disadvantages of smoking
as fully as did the nonpsychiatric comparison smokers but
considered them less impressive than the advantages.
Also supporting psychopathologic commonality, both
patient groups exceeded the comparison subjects in their
reported preferences for smoking rather than other pleas-
ant activities, after age and Fagerstrom score were con-
trolled for (Figure 2). Again, there was no difference
between the schizophrenic and depressed patients. As
shown in Figure 2, the average nonpsychiatric comparison
subject chose smoking over other rewards in about 33% of
the 15 choices (mean score=5.27, SD=1.04), whereas the
average schizophrenic and depressed patients preferred
smoking in about 67% of the choices (schizophrenic:
mean=10.42, SD=1.88; depressed: mean=10.04, SD=1.87).
Finally, controlling for age and Fagerstrom, we found
that the groups differed in the magnitude of the rewards
they would find necessary in order to quit smoking (Figure
3). Again, the schizophrenic (mean score=102.65, SD=
2.15) and depressed (mean=102.62, SD=2.52) smokers
failed to differ from each other. Both patient groups felt
that quitting would require substantially more rewards
than did the comparison smokers (mean=69.35, SD=7.93).
Discussion
The results of this study indicate that both schizophrenic
and depressed smokers associate greater advantages and
reward value with cigarette smoking than do individuals
without psychiatric disorders who smoke as heavily. There
were virtually no differences between the patient groups.
The findings also show that the patients appreciated the
drawbacks of smoking as fully as the nonpsychiatric com-
parison subjects but considered them outweighed by
smoking’s advantages. In contrast, the comparison sub-
jects perceived the pros and cons of smoking as nearly
equivalent. When asked to choose between smoking and
other pleasant activities, the schizophrenic and depressed
smokers chose smoking twice as often as the comparison
subjects. Finally, the incentives that the patients said they
would need to quit smoking approached the maximal pos-
sible reward magnitude, markedly exceeding what the
comparison subjects said they would need.
The rarity of smoking cessation by schizophrenic and
depressed smokers has remained largely unexplained.
Candidate explanations have been that patients 1) have
minimal contact with antismoking messages and little ac-
cess to smoking cessation treatment, 2) are characterized
by a preponderance of heavy smokers, or 3) experience
nicotine effects on psychopathologic vulnerabilities that
render the smoking habit exceptionally rewarding and dif-
ficult to break. The current prevalence of nonsmoking en-
vironments and media antismoking messages, coupled
with the availability of over-the-counter cessation aids,
make it increasingly implausible that psychiatric patients
smoke because they are unaware of the risks or lack access
to cessation resources. Indeed, the current findings con-
tradict that premise, by showing that psychiatric patients
FIGURE 1. Degree of Endorsement of 14 Pros and 14 Cons
of Smoking by Schizophrenic, Depressed, and Nonpsychi-
atric Heavy Smokersa
a Assessed with a modified version of the Decisional Balance Scale
(44).
b 14=disagrees with all 14 pros/cons of smoking, 42=strongly agrees
with all 14 pros/cons of smoking.
c Significant difference among groups (F=75.6, df=2, 72, p=0.0001).
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appreciate the disadvantages of smoking as adequately as
smokers without major psychopathology.
These are, to our knowledge, the first findings to demon-
strate that both schizophrenic and depressed patients at-
tribute greater-than-normal reward value to cigarette
smoking and that the difference is unlikely to be explained
by variation in nicotine exposure. All three study groups, in-
cluding the nonpsychiatric comparison subjects, smoked
heavily (nearly two packs per day), and there was no differ-
ence among them in the amount smoked. It is interesting
that, despite smoking equally heavily, the patients reported
features (such as smoking soon after awakening) that sug-
gest greater physical dependence on nicotine. That patients
apparently exhibit greater nicotine dependence than non-
psychiatric comparison subjects, even given seemingly
comparable nicotine exposure, is intriguing. Nevertheless,
we think it unlikely that group differences in nicotine de-
pendence can explain the greater reward value of cigarettes
for smokers with other psychiatric disorders because our
analyses controlled for them.
The lack of difference between schizophrenic and de-
pressed smokers was surprising, especially given the
higher prevalence of smoking usually observed among
schizophrenic patients. Two explanations suggest them-
selves. One is that, by studying only heavy smokers, we se-
lected depressed patients who were unrepresentative of
that disorder but held many sociodemographic features in
common with schizophrenic patients. An alternative ex-
planation that seems more likely is that there may be
genuine commonalities in what hooks schizophrenic and
depressed smokers to their cigarettes. Plausibly, schizo-
phrenic and depressed individuals share certain neurobi-
ological features, either premorbidly or as a consequence
of illness, medications, comorbid addictions, or even
chronic nicotine exposure, that render nicotine a particu-
larly appealing drug to self-administer. Earlier we posited
that nicotine’s ability to trigger dopamine release in me-
solimbic reward centers might render smoking one of the
few reinforcers able to overcome the anhedonia that char-
acterizes schizophrenia and depression (28). Beneficial ef-
fects on other core affective and cognitive psychopatho-
logic vulnerabilities may also occur (46), mediated by
nicotine’s effects on serotonin, glutamate, GABA, and
acetylcholine (36).
Certain limitations of the current study need to be con-
sidered. First, the findings can be interpreted only as indi-
cating that cigarette smoking (not necessarily nicotine)
has disproportionate reward value for schizophrenic and
depressed smokers. Laboratory experimental studies are
needed to differentiate between the pharmacological ef-
fects of nicotine and the sensory effects of smoking on
perceived reward. Second, the data were based on self-re-
ports provided by psychiatric patients. Can such self-re-
ports, particularly those of patients with schizophrenia,
be considered valid? Some reassurance derives from the
consistent pattern of group differences across all mea-
sures of smoking’s reward value, from how closely the re-
ports of the schizophrenic patients resembled those of
the depressed outpatients, and from the fact that all of the
groups seemed well informed of the negative conse-
quences of smoking. Nevertheless, it would be advanta-
geous for the results to be replicated by behavioral proto-
cols not requiring participants to have any insight into
their own motivations (see reference 47). Third, the gen-
eralizability of the findings remains unclear. The patients
with psychiatric disorders had relatively high levels of
functioning: the groups included only patients who were
able to live outside the hospital, manage their own ap-
pointment schedules, and pass the mental state entry cri-
teria imposed for this study. It cannot be assumed that the
results, perhaps particularly those showing full awareness
of the disadvantages of smoking, would generalize to
more severely impaired patient populations.
The results may have implications for smoking cessa-
tion treatment. Research guided by the transtheoretical
model has shown that people progress through a series of
stages in their readiness to initiate change in health-re-
lated behavior (48). The patients’ motivational balance
sheet, in which the pros of smoking outweighed the cons,
is typical of people in the precontemplative stage of readi-
ness to quit smoking. Smokers in the precontemplative
stage recognize intellectually that they need to quit, but
they are not actually intending to make an attempt to quit
FIGURE 3. Amounts of 15 Rewards Considered Necessary
to Quit Smoking by Schizophrenic, Depressed, and Non-
psychiatric Heavy Smokers
a 15=minimal other rewards needed to quit smoking (needs only 1
unit of each of 15 rewards), 150=maximal other rewards needed to
quit smoking (needs 10 units of each of 15 rewards).
b Significant difference among groups (F=12.5, df=2, 73, p=0.0001).
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in the foreseeable future. To progress to the stage of con-
templation, which involves seriously thinking about mak-
ing an attempt to quit, the smoker needs to experience a
decline in the perceived advantages of smoking. The
heavy-smoking nonpatient participants in this study dif-
fered from the patients in showing a typical motivational
balance for contemplators: one in which the perceived ad-
vantages of smoking have lessened and are roughly equiv-
alent to its perceived drawbacks. The contemplator’s like-
lihood of moving into the stage of preparing to make a quit
attempt will be enhanced by experiences that enhance
feelings of self-efficacy about being able to quit.
Enrollment in smoking cessation treatment has been
shown to be unproductive until a smoker reaches the
stage of at least contemplating, if not actively preparing to
make, a quit attempt (49). If the patients in the current
study are representative of other schizophrenic and de-
pressed smokers in being at a very early stage of readiness
to quit, referral to smoking cessation treatment would be
premature and ineffectual. More appropriate and needed
forms of tobacco control intervention for smokers with
psychiatric disorders may involve motivational interview-
ing and other brief interventions that overcome barriers to
considering healthy behavior change (50).
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